25-Mar-2026
Mesoblast Grants New Director Options Following 2025 AGM Approvals
TipRanks (Mon, 23-Mar 8:22 AM ET)
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Globe Newswire (Wed, 18-Mar 11:30 AM ET)
Mesoblast to Host R&D Day on April 8, 2026
Globe Newswire (Tue, 17-Mar 7:19 PM ET)
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Globe Newswire (Wed, 11-Mar 7:21 PM ET)
Strong Ryoncil® Performance Drives Revenue Gains and Expands Mesoblast's Growth Pipeline
Market Chameleon (Fri, 27-Feb 3:44 AM ET)
Ryoncil Profits Underpinning Substantial Growth Pipeline
Globe Newswire (Thu, 26-Feb 7:42 PM ET)
Mesoblast Financial Results and Corporate Update Webcast
Globe Newswire (Fri, 20-Feb 7:00 AM ET)
Globe Newswire (Wed, 11-Feb 6:27 PM ET)
Ryoncil Net Revenues Increase for the Quarter to US$30M
Globe Newswire (Wed, 28-Jan 6:54 PM ET)
Globe Newswire (Mon, 26-Jan 6:45 PM ET)
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of March 25, 2026, MESO stock price climbed to $15.65 with 314,325 million shares trading.
MESO has a beta of 1.58, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.16 to the broad based SPY ETF.
MESO has a market cap of $2.02 billion. This is considered a Mid Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $51 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $34 million and exceeded earnings estimates by $.17.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, IBBQ, APIE, BIB.
MESO has underperformed the market in the last year with a return of +10.9%, while the SPY ETF gained +15.4%. In the last 3 month period, MESO fell short of the market, returning -19.3%, while SPY returned -4.6%. However, in the most recent 2 weeks MESO has outperformed the stock market by returning +0.1%, while SPY returned -2.6%.
MESO support price is $13.78 and resistance is $14.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.